Bernie Fernandes, State Manager (WA & SA) of Sequoia Financial Group (ASX:SEQ), talks with CEO and Managing Director Garry Crole. Bernie shares insights for advisors from his long career.
15 Feb 2023 - The bench-scale test work indicates the alternative process has the potential to improve processing reliability and feed-salt quality, positively impact costs and accelerate production ramp-up.
31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
21 Aug 2020 - DigitalX Limited (ASX:DCC) Executive Director Leigh Travers provides an update on the company's strategy, its focus on blockchain consulting and development for the enterprise market and digital asset management, the impact of COVID-19, and priorities.
05 Apr 2023 - North Stawell Minerals Limited (ASX:NSM) CEO Russell Krause provides an update, discussing the company's progress to date, the most prospective targets, and milestones ahead.
22 May 2023 - Kalamazoo Resources Limited (ASX:KZR) CEO and Chairman Luke Reinehr discusses plans to spin out the company's lithium projects into a new ASX-listed exploration company in an agreement with TSX-listed Canadian gold miner Karora Resources.
28 Feb 2024 - Tim Mason - CEO - Eagle Mountain Mining Limited (ASX:EM2), is a copper focused exploration and development Company with a key objective of becoming a low emission producer at its high-grade Oracle Ridge project in Arizona, USA, to supply the rapidly growing green energy market.
29 Mar 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meeting its primary endpoint of progression-free survival and what it means for Immutep.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
